Dementia of Alzheimer's Type
1 medicine
Dementia of Alzheimer's type is a progressive brain disorder that gradually erodes memory, thinking, and the ability to manage daily life, usually managed with cholinesterase inhibitors alongside non-drug support.
Key facts
- Dementia of Alzheimer's type is the most common form of dementia, making up roughly 60-70% of all cases.
- It develops when abnormal protein deposits build up in the brain, damaging nerve cells and gradually disrupting memory, reasoning, and behaviour.
- Cholinesterase inhibitors such as rivastigmine, donepezil, and galantamine, part of the neurology category, can slow cognitive decline, and memantine may be added for moderate to severe stages; there is no cure.
- A sudden, rapid change in mental function is not typical and needs prompt medical assessment.
How the condition progresses
Early signs are often subtle: forgetting recent conversations, losing track of dates, or struggling with familiar tasks. Over months and years, difficulties deepen to include confusion about time and place, trouble recognising family members, and changes in mood or personality. In later stages, people may need help with basic daily activities, including eating, dressing, and moving around safely. Onset is usually after age 65, though early-onset cases do occur, and the pace of decline varies considerably from person to person.
What causes it
The underlying process is the buildup of two abnormal proteins in the brain, amyloid plaques and tau tangles, which interfere with communication between nerve cells and eventually cause them to die. Age is the strongest risk factor, but genetics, cardiovascular health, and lifestyle all play a part. Conditions that damage blood vessels, high blood pressure, diabetes, and high cholesterol among them, are linked to a higher risk, which is why managing overall vascular health is thought to help protect the brain too.
Approaches to treatment
There is no cure, but medicines within neurology can slow cognitive decline and manage symptoms for a period. Cholinesterase inhibitors such as rivastigmine, donepezil, and galantamine work by reducing the breakdown of acetylcholine, a chemical messenger important for memory and learning, and are generally used for mild to moderate disease. Memantine works differently, regulating a separate chemical messenger called glutamate, and is typically added for moderate to severe stages, sometimes alongside a cholinesterase inhibitor. Non-drug support, structured routines, cognitive activities, and carer involvement remain an important part of overall management alongside medicine.
When to see a doctor
Arrange an assessment for persistent memory or thinking problems that affect daily life. If someone shows a sudden and rapid change in mental function, seek medical attention promptly, since this can signal a different or additional cause that needs urgent evaluation.
This page is educational and does not replace advice from a doctor or pharmacist who knows your health history.